Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CAB-ROR2-ADC · 1 trial · 4 indications
Assess dose limiting toxicity as defined in the protocol
Frequency and severity of AEs and/or SAEs
Proportion of patients who achieve a confirmed CR or PR
| Arm | Type | Description |
|---|---|---|
| Monotherapy - CAB-ROR2-ADC (BA3021) alone | EXPERIMENTAL | BA3021 alone Q2W dosing regimen |
| Combination Therapy | EXPERIMENTAL | CAB-ROR2-ADC (BA3021) with PD-1 inhibitor |
| Name | Type | Description |
|---|---|---|
| CAB-ROR2-ADC | BIOLOGICAL | Conditionally active biologic anti-ROR2 antibody drug conjugate |
| PD-1 inhibitor | BIOLOGICAL | PD-1 inhibitor |
Inclusion Criteria: * Patients must have histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumor and have failed all available standard of care (SoC) therapy and for whom no curative therapy is available or who are not eligible, intolerant to or refuse stan...
Top 20 of 84 competitors
CAB-ROR2-ADC is an investigational monoclonal antibody being studied for the treatment of non-small cell lung cancer (NSCLC). It is also being evaluated in other solid tumors, including triple negative breast cancer, melanoma, and head and neck cancer, as part of a clinical trial.
CAB-ROR2-ADC is being developed by BioAtla, Inc., a biopharmaceutical company. BioAtla is publicly traded on the Nasdaq under the ticker symbol BCAB.
CAB-ROR2-ADC is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in a Phase 1 trial that has been completed.
CAB-ROR2-ADC has been studied in one clinical trial, identified as NCT03504488. This trial was a Phase 1 study that evaluated the safety and efficacy of CAB-ROR2-ADC in patients with triple negative breast cancer, head and neck cancer, non-small cell lung cancer, and melanoma. The trial enrolled 132 participants and has been completed.
CAB-ROR2-ADC is a specific antibody-drug conjugate developed by BioAtla. No alternative names for this drug have been disclosed in the available information.